SARS-CoV-2: Origin, Evolution, and Targeting Inhibition

Shuo Ning(Ministry of Education of the People's Republic of China), Feng Wang(First Affiliated Hospital of Zhengzhou University), Beiming Yu(Beijing Institute of Technology), Yanfeng Wang(Beijing Institute of Technology)
Frontiers in Cellular and Infection Microbiology
June 17, 2021
10.3389/fcimb.2021.676451
Cited by 30

Related Papers

The laboratory tests and host immunity of COVID-19 patients with different severity of illness
|JCI Insight|2020|576
USP14: Structure, Function, and Target Inhibition
|Frontiers in Pharmacology|2022|133
Fungal Microbiota Profile in Newly Diagnosed Treatment-naïve Children with Crohn’s Disease
|Journal of Crohn s and Colitis|2016|69
Surveillance of SARS-CoV-2 in the environment and animal samples of the Huanan Seafood Market
|Research Square|2022|51
Epigallocatechin-3-gallate inhibits the proliferation and migration of human ovarian carcinoma cells by modulating p38 kinase and matrix metalloproteinase-2
|Molecular Medicine Reports|2014|41